Sun Pharmaceuticals reported a 5% increase in its consolidated net profit for the second quarter of FY 2024. The company's revenue also rose by 11.3% and its EBITDA came in at Rs 3,179 crore. Sun Pharma's India formulation sales increased by 11.1%, while US formulation sales increased by 4.2%. Sun Pharma also highlighted the positive phase-3 data for Nidlegy in patients with melanoma. The company's API business saw a 5.1% increase in external sales.